Respiratory Disease in Poland



Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strategies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

Better...

- Prevention of respiratory diseases
- Access to the right treatment at the right time
- Action on reducing inequalities
- Prioritisation of research, data and insight to improve care

The Polish Coalition of Healthy Lungs was established on the initiative of the Polish Lung Society in December 2022. Upon its establishment, five signatories from the pulmonary care sector have joined: Institute of Tuberculosis and Lung Diseases, Polish Society of Lung Diseases, Polish Society of Paediatric Pneumonology, National Consultant in the field of lung diseases and National Consultant in the field of children's lung diseases. The coalition is growing with 20 partners.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders in promoting lung health across Poland by developing national strategies.



deaths from respiratory

diseases











Asthma 9.8zł billion

16.5zł billion

Lung Cancer 48zł billion







Mesothelioma 567.5zł million



Tuberculosis 988.3zł million



Interstitial lung disease 1.3zł billion



COVID-19 122zł billion



Pulmonary arterial hypertension 146.9zł million



people living with

respiratory diseases

This initiative is made possible with the contributions of the partner organisations who all support the IRC's goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.